RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating claims against REGENXBIO Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether REGENXBIO issued false or misleading statements or failed to disclose critical information to investors [2]. - A press release from REGENXBIO on January 28, 2026, revealed that the FDA placed a clinical hold on its gene therapy RGX-111 for treating MPS I due to a case of neoplasm in a participant from a Phase I/II study [2]. - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the clinical studies [2]. Group 2: Market Reaction - Following the announcement of the FDA's clinical hold, shares of REGENXBIO fell by 17.9% on the same day [2].